Xtant Medical (NYSE American: XTNT) has announced the commercial launch of its next-generation innovative synthetic bone graft in the nanOss line, Strata.
According to Xtant, the nanocrystalline structure of hydroxycarbonapatite, used in the nanOss Strata, is designed to closely mimic human bone and increase the surface area for improved osteoconductivity and stimulation of the patient’s cellular activity on the surface of the graft after implantation.
In a statement, Sean Browne, President and CEO of Xtant, commented, “By building on the clinical success of our nanOss products, Strata further demonstrates our commitment to innovation in regenerative medicine. We are excited to introduce this new technology to help our surgeon customers improve the surgical outcomes of their patients.”
